Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration. [electronic resource]
Producer: 20140219Description: 1815-27 p. digitalISSN:- 1539-2864
- Aged
- Aged, 80 and over
- Alleles
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Bevacizumab
- Complement C3 -- genetics
- Complement Factor H -- genetics
- Exudates and Transudates
- Female
- Genotype
- Humans
- Interleukin-8 -- genetics
- Intravitreal Injections
- Male
- Middle Aged
- Pharmacogenetics
- Polymerase Chain Reaction
- Polymorphism, Single Nucleotide
- Promoter Regions, Genetic -- genetics
- Prospective Studies
- Proteins -- genetics
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Visual Acuity -- physiology
- Wet Macular Degeneration -- diagnosis
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.